Dupont Capital Management’s AtriCure ATRC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-9,039
Closed -$594K 1653
2022
Q1
$594K Sell
9,039
-800
-8% -$51.8K 0.02% 688
2021
Q4
$684K Buy
9,839
+4,794
+95% +$348K 0.02% 686
2021
Q3
$351K Sell
5,045
-6,602
-57% -$508K 0.01% 1024
2021
Q2
$924K Hold
11,647
0.02% 670
2021
Q1
$763K Sell
11,647
-2,389
-17% -$147K 0.02% 699
2020
Q4
$781K Sell
14,036
-16,963
-55% -$733K 0.02% 662
2020
Q3
$1.24M Sell
30,999
-2,077
-6% -$88.1K 0.03% 427
2020
Q2
$1.49M Sell
33,076
-11,270
-25% -$491K 0.03% 384
2020
Q1
$1.49M Buy
44,346
+38,744
+692% +$1.39M 0.04% 346
2019
Q4
$182K Buy
+5,602
New +$159K ﹤0.01% 1170

Other funds holding ATRC

Dupont Capital Management's ATRC Position: Q2 2022 in Review

Dupont Capital Management sold out of AtriCure (ATRC) in Q2 2022, closing a stake of 9,039 shares — an estimated $594K sold.

Dupont Capital Management first reported a position in ATRC in Q4 2019 and held it in 10 quarters. The position peaked at $1.49M in Q1 2020. 213 funds tracked by Wall St. Rank hold ATRC as of Q2 2022.

  • Dupont Capital Management reported no remaining AtriCure position as of Q2 2022 after selling out during the quarter.
  • Dupont Capital Management sold 9,039 AtriCure shares in Q2 2022, an estimated $594K.
  • Dupont Capital Management first reported a position in AtriCure in Q4 2019 and held it in 10 quarters.
  • Dupont Capital Management's AtriCure position peaked at $1.49M in Q1 2020.
  • 213 funds tracked by Wall St. Rank held AtriCure as of Q2 2022.

Based on Dupont Capital Management's 13F filing for Q2 2022, filed 26 Jul 2022.